Biospace med Expands U.S. Market Penetration with `EOS`, which Cuts Radiation up to 90% vs. Conventional X-Rays

Company`s founder, Nobel Prize-winning physicist Professor Georges Charpak,
receives `Centenary Medal` from French Radiological Society
CAMBRIDGE, Mass. & PARIS--(Business Wire)--
Biospace med announced today that it continues to penetrate the U.S. market with
its FDA-cleared `EOS` x-ray imager-the world`s first ultra-low-dose x-ray
technology-recently adding new customers in the Midwest and Southeast regions of
the United States. In addition, Professor Georges Charpak, inventor of the EOS
technology, has received the `Centenary Medal` from the French Radiological
Society (SFR), the esteemed organization`s highest honor.

EOS can capture head-to-toe images of patients in a standing, weight-bearing
position with a dramatic reduction in radiation dose-up to 10 times less than a
conventional x-ray and up to 1000 times less than a CT (Computed Tomography)
scan. Additionally, EOS images are designed to provide sharp detail and empower
physicians to better diagnose and plan an effective course of treatment.

"We are very pleased to announce additional installations of our ultra-low-dose
EOS x-ray imager in new markets across the United States," said Marie Meynadier,
Ph.D., chief executive officer of Biospace med. "Now that we have a beachhead in
two new regions of the United States, we look forward to meeting the numerous
healthcare institutions in these new markets that are still imaging patients
with a conventional digital x-ray, as they are in the front rank of candidates
to adopt EOS.

"In addition, because EOS uses significantly less radiation than a conventional
x-ray or CT scan, it represents a remarkable advance in musculoskeletal imaging,
as all other technologies deliver a substantial dose of radiation to the
patient," added Dr. Meynadier.

"Further, we are extremely proud that Professor Charpak has been recognized for
his seminal contribution to low-dose x-ray imaging," said Dr. Meynardier. "EOS
is a major breakthrough in the safe and effective imaging of patients. Professor
Charpak is most certainly deserving of the SFR`s highest award."

About Professor Georges Charpak

Born in 1924 in Dabrovica, Poland, Charpak moved to France with his family in
1929. At the start of WW II, he joined the French Resistance. Arrested in 1943,
Charpk was sent to Dachau concentration camp until its liberation in 1945. After
his return to France, he embarked on a career in nuclear physics. Charpak
received a Ph.D. in 1955 from the College de France, Paris, where he worked in
the laboratory of Frédéric Joliot-Curie. In 1959 he joined the staff of European
Laboratory for Particle Physics at CERN in Geneva and in 1984 also became the
Joliot-Curie professor at the School of Advanced Studies in Physics and
Chemistry, Paris. He was made a member of the French Academy of Science in 1985.
Charpak received the Nobel Prize in physics in 1992 for his invention and
development of particle detectors.

About Biospace med

Biospace med was founded on a unique partnership between Nobel Prize-winning
physicist Georges Charpak, Ph.D., and a team of biomedical engineers, orthopedic
surgeons and radiologists who have developed a complete orthopedic imaging
solution. The Company`s lead product, EOS ultra-low-dose 2D/3D x-ray imager,
allows full-body imaging of patients in a weight-bearing position that enables
global assessment of balance and posture. EOS is a total solution in orthopedic
imaging now available in the U.S. since receiving FDA 510(k) clearance. The
Company has corporate headquarters in Cambridge, Mass., and Paris, as well as an
office in Montreal, and is targeting a $2 billion orthopedic imaging
marketplace. The Company`s U.S. headquarters is located at 185 Alewife Brook
Parkway, #410, Cambridge, Mass. (toll free: +1-866-933-5301). Learn more at
www.biospacemed.com.

Ronald Trahan Associates Inc.
Ronald C. Trahan, 508-359-4005, x108

Copyright Business Wire 2009